Soraya Bekkali is a Venture Partner at SV and CEO of Cellinta, an SV portfolio company. She joined the SV Venture Partner Program in September 2020.
Prior to joining SV, Soraya was CEO and director of the board of Gyroscope Therapeutics, a UK based company developing genetically defined therapies for ocular diseases such as age-related macular degeneration. Whilst at Gyroscope she led the organization towards clinical stage, Series B and finally to the merger with US based Orbit Medical commercializing surgical device for sub-retinal drug delivery.
Prior to joining Gyroscope, Soraya served as SVP CMO at Lysogene, a Boston-Paris biotech developing gene therapy for rare CNS disorders. As a member of the executive team, she contributed to the successful listing of the company on the European Stock Exchange Euronext.
Soraya started her career in academia before joining industry with Orphan Europe, a European based company dedicated to the development and commercialization of orphan drugs. She then joined Sanofi for 10 years where she held increasing leadership positions, leading global drug development programs in cardiovascular and Ophthalmology. In Soraya's final role as Global Business Unit Head, she led an integrated business unit dedicated to Ophthalmology following the acquisition and integration of a biotech, Fovea Pharmaceuticals, within Sanofi. In this capacity, she drove the Sanofi strategy towards investing into ocular gene therapy.
M.D. from Paris University specializing in Clinical Pharmacology and Biostatistics.